The ABI1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human SK-HEP-1 liver adenocarcinoma epithelial cell line, engineered to disrupt the ABI1 gene. This heterogeneous knockout pool is generated by non-clonal CRISPR/Cas9-mediated gene editing, providing a loss-of-function model for ABI1 without exogenous selection markers. Researchers can use these cells immediately for functional studies of ABI1-dependent actin dynamics and signaling in liver cancer.
SK-HEP-1 is a human hepatocellular carcinoma cell line originally isolated from ascites of a patient with liver adenocarcinoma, exhibiting epithelial characteristics. Widely used as an HCC model, these cells are suitable for investigating tumor cell migration, invasion, and metastasis. Their well-characterized background and retention of relevant signaling networks make them an appropriate host for studying ABI1 ablation in a liver cancer context.
ABI1 is a core component of the WAVE regulatory complex (WRC), interacting with WASF2, CYFIP1, NCKAP1, and BRK1 to regulate Arp2/3-mediated actin nucleation and lamellipodia formation. ABI1 functions downstream of Rac1 GTPase and is phosphorylated by Abl kinases (ABL1, ABL2), linking signals from EGFR, PDGFR, and integrin receptors to cytoskeletal reorganization. Disruption of ABI1 impairs WRC assembly, reducing Arp2/3-dependent actin branching and compromising cell migration and adhesion.
In SK-HEP-1 HCC cells, ABI1 knockout is expected to severely impair lamellipodia-based motility, invasive capacity, and adhesion??phenotypes critical for HCC metastasis. This model allows dissection of WRC-mediated actin polymerization in liver cancer cell dissemination and exploration of Abl/Rac1 convergence on the WRC. It provides a physiologically relevant tool for validating ABI1 as an anti-metastatic target and studying 2D/3D migration, ECM interactions, and growth factor-driven chemotaxis.
These polyclonal knockout cells support assays for actin dynamics and cancer cell invasion, including scratch wound healing, transwell migration/invasion, actin polymerization assays, and co-immunoprecipitation of WRC components. Phospho-Abl western blotting and immunofluorescence for F-actin further enable signaling and cytoskeletal analyses. Applications include HCC metastasis studies, pharmacological screening of WRC or Abl inhibitors, and drug target validation. For further information, please contact Ascent Research.
